Apomorphine for motor fluctuations and freezing in Parkinson's disease

OBJECTIVE: To review the pharmacokinetics and use of apomorphine in patients with Parkinson's disease; to report a case of beneficial outcome with apomorphine in a patient with Parkinson's disease with severe levodopa "on-off" fluctuations and freezing; and to outline the types of patients or situations where apomorphine may be useful. DATA SOURCES: Case reports, review articles, and relevant clinical studies identified by a MEDLINE search of the English-language literature published between 1975 and October 1994. STUDY SELECTION: Because all but 2 reports were of open-label design with small sample sizes, all studies identified were evaluated. DATA EXTRACTION: The following data were extracted from each study: apomorphine treatment duration, dosing, onset, duration, and adverse effects. The following efficacy variables were extracted: percent decrease in off periods, improvement in parkinsonian symptoms, and percent decrease in levodopa dosage. DATA SYNTHESIS: Efficacy of apomorphine following subcutaneous, rectal, sublingual, and intranasal dosage forms are evaluated. We also describe the use of apomorphine in a patient with Parkinson's disease who experienced on-off fluctuations and freezing. Based on these reports, recommendations for patient selection, product selection, and apomorphine dosing guidelines are presented. CONCLUSIONS: Apomorphine decreases off time, freezing, and levodopa requirements in patients with Parkinson's disease. It can be administered via a number of different nonoral routes; however, subcutaneous apomorphine is the most extensively studied. Rectal, sublingual, and intranasal routes also have been shown to provide benefit in motor fluctuations, but differ from the subcutaneous route in onset of action, duration of effect, and adverse effect profile.

This article has been cited by other articles:

				H. A. Lashuel, D. M. Hartley, D. Balakhaneh, A. Aggarwal, S. Teichberg, and D. J. E. Callaway New Class of Inhibitors of Amyloid-beta Fibril Formation. IMPLICATIONS FOR THE MECHANISM OF PATHOGENESIS IN ALZHEIMER'S DISEASE J. Biol. Chem., November 1, 2002; 277(45): 42881 - 42890. [Abstract] [Full Text] [PDF]

				K. Kompoliti, Q. E. Wang, C. G. Goetz, S. Leurgans, and R. Raman Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease Neurology, January 25, 2000; 54(2): 458 - 458. [Abstract] [Full Text] [PDF]

				K. Pietz, P. Hagell, and P. Odin Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up J. Neurol. Neurosurg. Psychiatry, November 1, 1998; 65(5): 709 - 716. [Abstract] [Full Text]